Search results: (10000)
News Assessment of Infection Risk in Patients with Multiple Sclerosis Treated with Various DMDs
Although the increased risk of infections with some disease-modifying drugs (DMDs) is known, we still lack sufficient real-world clinical data to evaluate and compare the risk levels of individual drugs. A Swedish study therefore provides information about these risks with glatiramer acetate, beta interferon, natalizumab, fingolimod, and rituximab in the treatment of multiple sclerosis (MS).
News Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years – Findings from Post-hoc Analysis of Studies
The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in children over 6 years old. Post-hoc analyses of two clinical studies focused on its safety profile and pharmacokinetics in the pediatric population.
News Current Options and Prospects for Effective Antiemetic Treatment in an Effort to Increase Adherence of Oncological Patients to Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) is strongly associated with treatment in the minds of many oncology patients, and its occurrence is rated as one of the most dreaded and stressful complications. For most patients, adherence to recommendations for antiemetic prophylaxis can successfully prevent the occurrence of CINV. A review article published last year by an international team of authors in the journal Future Oncology provides an overview of the current spectrum of options in CINV prophylaxis, focusing on the first combined preparation in this indication, containing the active substances netupitant and palonosetron.
News A Brief History of Deep Vein Thrombosis Treatment – From Antiquity to the Present
Deep vein thrombosis is among the common diseases that have accompanied humanity since its inception. Due to the low specificity of its clinical presentation (in contrast to, for example, varicose veins of the lower limbs), however, the disease long went undescribed in literature. The first descriptions of deep vein thrombosis did not appear until the Middle Ages – and from that moment, the gradual development of its treatment began. We offer you a brief but remarkable historical excursion in three stages.
News Current Recommendations of the American Society of Hematology for the Prevention of Thromboembolic Disease and Duration of Prophylaxis in Patients Undergoing Major Surgery
At the end of 2019, new recommendations were published by the American Society of Hematology (ASH) for the prevention of thromboembolic disease (VTE) in hospitalized patients. The new guidelines also addressed the duration of VTE prophylaxis in patients undergoing major surgical procedures.
News Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’
The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection fraction of the left ventricle (HFrEF). A recent sub-analysis of its results suggested that not only patients with a long-known diagnosis but also those with newly diagnosed HFrEF could benefit from the treatment if the possibility of its prescription in this indication arises.
News Effectiveness of Arginine in Tooth Cleaning Proven (Not Only) by Quantitative Light-Induced Fluorescence
There is no doubt about the benefits of toothpaste in daily dental care. Today, there are numerous studies proving that brushing without toothpaste does not have the same effectiveness as brushing with toothpaste. It is more effective and, thanks to active ingredients, can slow down or even reverse the development of tooth decay.
News Pertuzumab significantly extends the life of patients with metastatic breast cancer
The final results of the CLEOPATRA clinical trial show that patients with HER2-positive metastatic breast cancer achieve 8-year overall survival of 37% with the targeted treatment combination of pertuzumab + trastuzumab + docetaxel.
News Educational Quiz (For Downtime)
The following quiz has been prepared for you as an activity for relaxation and unwinding from today's hectic days. In an easy manner, it will refresh your knowledge about immune cells and may even offer some education or entertainment.
News Care for Dental Prostheses: What Did Clinical Study Results Reveal?
Dental prostheses are one of the most common solutions for missing teeth, especially in the elderly population. It is estimated that by 2050 up to 2 billion people will be aged 60 or older. Currently, it's not even half that, so it's likely that the number of people with dental prostheses will continue to increase. What do current research findings on dental prosthesis care reveal, and which cleaning methods have been evaluated as truly effective?
News Should patients with primary immunodeficiencies fear COVID-19 more than the general population?
The body fights the new SARS-CoV-2 virus, which causes COVID-19, in a similar way to other viral infections - by intensely engaging the immune system. But what if it's weakened?
News How do IL-17 and IL-23 inhibitors fare in the treatment of psoriasis in direct comparison?
A recent study published in the British Journal of Dermatology is only the second paper to provide a direct comparison of the efficacy and onset speed of treatment with IL-17 and IL-23 inhibitors in patients with moderate to severe plaque psoriasis. The authors monitored the early response to treatment (at week 12), and the efficacy and safety of ixekizumab and guselkumab.
News Direct Comparison of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis
The final results of the direct comparison of ixekizumab and adalimumab in the therapy of biologic-naïve patients with psoriatic arthritis were presented at the annual conference of the American College of Rheumatology (ACR/ARP) in November 2019 in Atlanta.
News Patient Evaluation of Durvalumab Treatment Results
The interim analysis results of the PACIFIC study, which monitored the efficacy of durvalumab in the treatment of locally advanced unresectable non-small cell lung cancer (NSCLC), demonstrated a significantly longer progression-free survival (PFS) with this treatment compared to placebo. The following work analyzed one of the secondary objectives of the PACIFIC study − patient-reported outcomes (PRO).
News Index of Prostate Health as a Predictive Biomarker of Biopsy Outcome
As demonstrated by Spanish authors in their work published at the beginning of 2018, the Prostate Health Index (PHI) is a biomarker that can refine the prediction of prostate biopsy outcomes in men with elevated prostate-specific antigen (PSA) levels.